A practical reference on DAC: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-04-13 and is reviewed periodically as new material appears.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
| Property | Value | Notes |
|---|---|---|
| Molecular weight, DAC form | About 3647 Da | Varies with salt form |
| Molecular weight, non-DAC form | About 3358 Da | MOD GRF(1-29) |
| Solubility class | Water soluble | Also dissolves in polar solvents |
| Reported half-life, DAC form | About five to eight days | Values from human studies |
| Common synonyms | CJC-1295; MOD GRF(1-29) | Name depends on variant |
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
===== MeSH D08.811.277.450 – glycoside hydrolases ===== MeSH D08.811.277.450.066 – amylases MeSH D08.811.277.450.066.050 – alpha-amylase MeSH D08.811.277.450.066.100 – beta-amylase MeSH D08.811.277.450.114 – beta-fructofuranosidase MeSH D08.811.277.450.207 – chitinase MeSH D08.811.277.450.283 – dextranase MeSH D08.811.277.450.329 – disaccharidases MeSH D08.811.277.450.329.738 – sucrase MeSH D08.811.277.450.329.738.700 – sucrase-isomaltase complex MeSH D08.811.277.450.329.865 – trehalase MeSH D08.811.277.450.400 – alpha-L-fucosidase MeSH D08.811.277.450.410 – galactosidases MeSH D08.811.277.450.410.050 – alpha-galactosidase MeSH D08.811.277.450.410.100 – beta-galactosidase MeSH D08.811.277.450.410.100.500 – lactase MeSH D08.811.277.450.410.150 – ceramide trihexosidase MeSH D08.811.277.450.410.400 – galactosylceramidase MeSH D08.811.277.450.420 – glucosidases MeSH D08.811.277.450.420.050 – alpha-glucosidases MeSH D08.811.277.450.420.200 – cellulases MeSH D08.811.277.450.420.200.100 – beta-glucosidase MeSH D08.811.277.450.420.200.200 – cellulase MeSH D08.811.277.450.420.200.400 – cellulose 1,4-beta-cellobiosidase MeSH D08.811.277.450.420.200.450 – endo-1,3(4)-beta-glucanase MeSH D08.811.277.450.420.200.500 – glucan 1,3-beta-glucosidase MeSH D08.811.277.450.420.200.550 – glucan 1,4-beta-glucosidase MeSH D08.811.277.450.420.200.600 – glucan endo-1,3-beta-d-glucosidase MeSH D08.811.277.450.420.375 – glucan 1,4-alpha-glucosidase MeSH D08.811.277.450.420.450 – glycogen debranching enzyme system MeSH D08.811.277.450.420.475 – glycosylceramidase MeSH D08.811.277.450.420.475.400 – glucosylceramidase MeSH D08.811.277.450.426 – glucuronidase MeSH D08.811.277.450.483 – hexosaminidases MeSH D08.811.277.450.483.021 – acetylglucosaminidase MeSH D08.811.277.450.483.044 – alpha-N-acetylgalactosaminidase MeSH D08.811.277.450.483.112 – Beta-N-acetylgalactosaminidase MeSH D08.811.277.450.483.180 – Beta-N-acetylhexosaminidase MeSH D08.811.277.450.483.765 – Mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase MeSH D08.811.277.450.529 – hyaluronoglucosaminidase MeSH D08.811.277.450.560 – iduronidase MeSH D08.811.277.450.585 – isoamylase MeSH D08.811.277.450.625 – mannosidases MeSH D08.811.277.450.625.500 – alpha-mannosidase MeSH D08.811.277.450.625.750 – beta-mannosidase MeSH D08.811.277.450.642 – muramidase MeSH D08.811.277.450.692 – neuraminidase MeSH D08.811.277.450.737 – n-glycosyl hydrolases MeSH D08.811.277.450.737.099 – dna glycosylases MeSH D08.811.277.450.737.099.500 – DNA-formamidopyrimidine glycosylase MeSH D08.811.277.450.737.099.750 – thymine dna glycosylase MeSH D08.811.277.450.737.400 – nad+ nucleosidase MeSH D08.811.277.450.737.400.060 – adp-ribosyl cyclase MeSH D08.811.277.450.737.400.060.500 – antigens, cd38 MeSH D08.811.277.450.770 – oligo-1,6-glucosidase MeSH D08.811.277.450.770.800 – sucrase-isomaltase complex MeSH D08.811.277.450.800 – polygalacturonase MeSH D08.811.277.450.950 – xylosidases MeSH D08.811.277.450.950.249 – endo-1,4-beta xylanases MeSH D08.811.277.450.950.500 – xylan endo-1,3-beta-xylosidase
Protein nuclear magnetic resonance is performed on aqueous samples of highly purified protein. Usually, the sample consists of between 300 and 600 microlitres with a protein concentration in the range 0.1 – 3 millimolar. The source of the protein can be either natural or produced in a production system using recombinant DNA techniques through genetic engineering. Recombinantly expressed proteins are usually easier to produce in sufficient quantity, and this method makes isotopic labeling possible. The purified protein is usually dissolved in a buffer solution and adjusted to the desired solvent conditions. The NMR sample is prepared in a thin-walled glass tube.
Unlike a traditional incandescent lamp, an LED will light only when voltage is applied in the forward direction of the diode. No current flows and no light is emitted if voltage is applied in the reverse direction. If the reverse voltage exceeds the breakdown voltage, which is typically about five volts, a large current flows and the LED will be damaged. If the reverse current is sufficiently limited to avoid damage, the reverse-conducting LED is a useful noise diode. By definition, the energy band gap of any diode is higher when reverse-biased than when forward-biased. Because the band gap energy determines the wavelength of the light emitted, the color cannot be the same when reverse-biased. The reverse breakdown voltage is sufficiently high that the emitted wavelength cannot be similar enough to still be visible. Though dual-LED packages exist that contain a different color LED in each direction, it is not expected that any single LED element can emit visible light when reverse-biased. It is not known if any zener diode could exist that emits light only in reverse-bias mode. Uniquely, this type of LED would conduct when connected backwards.
Lieutenant Colonel James Edward Noel Bridgeman Shaw, Grenadier Guards, 559678; Brigade Major, Household Division, on the occasion of the Coronation of Their Majesties The King and The Queen. Nicholas Kester Smith, Director of Racing and Public Affairs, Ascot Racecourse. David William Courtenay Whelton, , Music Advisor, on the occasion of the Coronation of Their Majesties The King and The Queen. James Wyndham Williams, Music Advisor, on the occasion of the Coronation of Their Majesties The King and The Queen.
Knowledge Training and experience Reagents and materials preparation Characteristics of operational steps Calibration, quality control, and proficiency testing materials Test system troubleshooting and equipment maintenance Interpretation and judgment The Centers for Medicare & Medicaid Services (CMS) has the primary responsibility for the operation of the CLIA Program. Within CMS, the program is implemented by the Center for Medicaid and State Operations, Survey and Certification Group, and the Division of Laboratory Services. List of CLIA test complexity categorizations:
Sources: en.wikipedia.org
== History == In March 1963 the Danish pharmaceutical company Lundbeck began research into further agents for schizophrenia, having already developed the thioxanthene derivatives clopenthixol and chlorprothixene. By 1965 the promising agent flupenthixol had been developed and trialled in two hospitals in Vienna by Austrian psychiatrist Heinrich Gross. The long- acting decanoate preparation was synthesised in 1967 and introduced into hospital practice in Sweden in 1968, with a reduction in relapses among patients who were put on the depot.
Lexanopadol (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name), also known by its developmental code name GRT-6006, is an opioid receptor modulator which was under development for the treatment of pain. It is taken orally. The drug acts as a dual agonist of the μ-opioid receptor and nociceptin receptor. It is thought that the combination of these activities may confer enhanced analgesic efficacy. Lexanopadol was under development by Grünenthal. It reached phase 1 or 2 clinical trials prior to the discontinuation of its development, with no further development reported by 2016. The drug was a follow-on compound to cebranopadol (GRT-6005).
Other methods of weight loss include use of anti-obesity drugs that decrease appetite, block fat absorption, or reduce stomach volume. Obesity has been resistant to drug-based therapies, with a 2021 review stating that existing medications are "often delivering insufficient efficacy and dubious safety". Semaglutide has also become popular recently as an aid in weight loss. It is particularly beneficial for those with type 2 diabetes and obesity.
Ernest Beutler (September 30, 1928 – October 5, 2008) was a German-born American hematologist and biomedical scientist. He made important discoveries about the causes of a number of diseases, including anemias, Gaucher disease, disorders of iron metabolism and Tay–Sachs disease. He was also among the first scientists to identify X-inactivation as the genetic basis of tissue mosaicism in female mammals, and pioneered a number of medical treatments, including bone marrow transplantation techniques. Beutler was the Chairman of Medicine at the City of Hope Medical Center in Duarte, CA from 1959 until 1979 and served as a Professor, then Chairman, of the Department of Molecular and Experimental Medicine at The Scripps Research Institute in La Jolla, California from 1979 until 2008.
Sources: en.wikipedia.org
Mayer B. Davidson is an American physician and author who is an expert on diabetes and the algorithmic dosing of insulin. A Professor of Medicine at both the Charles R. Drew University of Medicine and Science and the David Geffen School of Medicine at UCLA, Davidson has studied algorithmic dosing of insulin as a means of controlling diabetes in insulin-using patients.
Isoelectric focusing (IEF), also known as electrofocusing, is a technique for separating different charged molecules by differences in their isoelectric point (pI). It is a type of zone electrophoresis usually performed on proteins in a gel that takes advantage of the fact that overall charge on the molecule of interest, i.e. the net charge density, is a function of the pH of its surroundings.
SELDI can be seen as a combination of solid-phase chromatography and TOF-MS. The sample is applied to a modified chip surface, which allows for the specific binding of proteins from the sample to the surface. Contaminants and unbound proteins are then washed away. After washing the sample, an energy absorbing matrix, such as sinapinic acid (SPA) or α-Cyano-4-hydroxycinnamic acid (CHCA), is applied to the surface and allowed to crystallize with the sample. Alternatively, the matrix can be attached to the sample surface by covalent modification or adsorption before the sample is applied. The sample is then irradiated by a pulsed laser, causing ablation and desorption of the sample and matrix.
Sources: en.wikipedia.org
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.
The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.